Synthetic Oxytocin Use in Spontaneous Labor Linked to Uterine Hyperactivity and Postpartum Hemorrhage

Spontaneous labor often requires intervention to manage uterine contractility issues, such as stagnation of cervical dilatation. Synthetic oxytocin, marketed as Syntocinon, has been a standard intervention since the 1960s to augment labor. However, its widespread use, with 58% of patients in spontaneous labor receiving it, raises concerns about potential adverse effects. The balance between effective labor augmentation and minimizing risks like uterine hyperactivity and postpartum hemorrhage (PPH) remains a critical challenge in obstetric practice.

This evaluation analyzed the existing modalities of synthetic oxytocin administration during spontaneous labor, drawing on data from the National Perinatal Survey of 2010 in France and reported literature. The study's scope included assessing the prevalence of oxytocin use and reviewing documented maternal and fetal adverse effects associated with its administration. It specifically examined the relationship between oxytocin dosage and the incidence of complications like uterine hyperactivity and PPH, as well as fetal heart rate abnormalities.

The evaluation confirmed the widespread use of synthetic oxytocin, with 58% of patients experiencing spontaneous labor receiving Syntocinon according to the 2010 National Perinatal Survey.

Maternal risks included uterine hyperactivity, which was found to increase in a dose-dependent manner with oxytocin administration, alongside reported increases in postpartum hemorrhage (PPH) and severe PPH. Fetal adverse effects primarily involved fetal heart rate abnormalities, also linked to uterine hyperactivity. Crucially, the analysis found no general association between oxytocin administration and excess neonatal morbidity or mortality, with the notable exception of patients with a scarred uterus, where such risks may be elevated. The phenomenon of OTR desensitization (oxytocin receptor desensitization) was also highlighted, suggesting that high or prolonged doses can attenuate myometrial response, potentially reducing effectiveness.